The Global 3D Bio-Printing Market is expected to grow at an approximate CAGR of 25% during the forecast period 2018-2023.
3D bio-printing is used to identify key compositional and architectural elements of a target tissue. This elements are used to create a design that is utilized by a bio-printer to generate that tissue in a laboratory environment. 3D Bioprinting has wide range of applications in the field of medicine, engineering, education, and others. Major factor driving the market is use of3D bio-printing to regenerative medicine addressing need for tissues and organs suitable for transplantation. Further, healthcare expenditure and research and development activities in 3D Bioprinting also influence the market growth.
North American 3D Bioprinting is the largest across the globe and is driven by increasing number of organ transplantation procedures, rising prevalence of chronic disorder such as liver failure, cardiovascular disorders, and others and growing adoption of 3D Bioprinting. Moreover, growing awareness about new technologies and needs organ transplantation at the end stage are also major factors affecting the market growth. The 3D Bioprinting market is exhibits growth due to developed healthcare infrastructure in the U.S. and presence of key players in the market. European 3D Bioprinting market also shows positive growth with rising government support for clinical trials and availability of funds for research. Focus on the applications of 3D Bioprinting in healthcare and overall development in the market are the major factors for the growth of the market. The market is led by Germany followed by France and U.K.
Get a Sample Copy of This Report @ https://www.marketresearchfuture.com/sample_request/869 .
In Asia Pacific, 3D Bioprinting market is ruled by extensive demand for technologically advanced medical devices for diagnosis and treatment of diseases. Rising share of healthcare in GDP and increasing foreign investment also fuel the growth of the market during the review period.
Competitive Analysis & News:
RGANOVO HOLDINGS, INC. (U.S.), CELLINK AB (Sweden), Bio3D Technologies (Singapore), Aspect Biosystems Ltd. (Canada), Stratasys Ltd. (U.S.), Materialise (U.S.), FATHOM (U.S.), Allevi (U.S.), ENVISIONTEC, INC. (Germany), Nano3D Biosciences, Inc.(U.S.), Cyfuse Biomedical K.K. (Tokyo), 3Dynamic Systems Ltd. (U.K), REGENHU (Switzerland), Poietis (France), and others are some of the key players for the global 3D bio-printing market are some of the prominent players at the forefront of competition in the global 3D Bioprinting market and top seven players are profiled in MRFR Analysis.
In 3D Bioprinting, significant increase in the number of the companies offering various products including number of healthcare IT solutions leads rising emphasis on use of information technology for healthcare management. Product launch, mergers, acquisition and collaboration are major strategic approaches of these players to achieve growth in the market.
Organovo Holdings, Inc.
The company use 3D Bioprinting technology to create functional 3D human tissues for medical research, surgical, and therapeutic applications. It product “ExVive” is the 3D bioprinted human tissues, that is used in Organomics- the study of living organs in-vitro. Another product, NovoGen Bioprinter platform manufactured by the company is used for translating tissue specific geometries and cellular components.
In December, 2017, the company was granted orphan drug designation for the treatment of alpha-1 antitrypsin deficiency (“A1AT”) with its 3D bioprinted liver therapeutic tissue by the U.S. Food and Drug Administration (FDA).
Get Attractive Discount on This Report @https://www.marketresearchfuture.com/check-discount/869 .
In May, 2017, Organovo Holdings, Inc. unrevealed the new preclinical data on 3D Bioprinted Human Liver Tissues at World Advanced Therapies and Regenerative Medicine Congress. The data exhibited extended survival and sustained functionality of 3D bioprinted human liver tissue when implanted into diseased animal models.
In May, 2017, the company announced a collaboration with University of Virginia for developing bioprinted tissues for volumetric muscle loss injury. The collaboration will benefit both the companies thereby bringing together the company’s bioprinting platform and research serve as a catalyst for the development of innovative treatments that meet critical unmet needs.
In October, 2016, 3D bioprinted human liver was introduced by the company as leading therapeutic tissue in preclinical development, for direct transplantation to patients.
Materialise is one of the major players in the market. The company undertakes 3D printing of anatomical models and offers 3D bioprinters.
In June 2017, Materialise improved 3D imaging and printing- clinical trials conducted in the U.S.
In March 2017, Materialise declared FDA clearance for its 3D-printed patient-specific radius and ulna osteotomy guides for children. In May 2017, the company announced it would start the production of 3D bioprinter using technology-HP Jet Fusion 3D 4200.
Inquire about This Report @ https://www.marketresearchfuture.com/enquiry/869 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Akash Anand
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –